drugset / Trial / NCT07455903
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the efficacy of ADT on prostate-specific membrane antigen (PSMA), a marker of prostate cancer, before and after scheduled ADT. Follow up will be 48 months your prostate removal to do a blood test and log if any new or worsening symptoms have occurred as a part of your standard-of-care (SOC).
Timeline
- Start
- 2026-04-23
- Primary completion
- 2029-10
- Completion
- 2030-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 80 mg | Subcutaneous |
| Subject | Leuprolide | Other / unclassified | 22.5 mg | Intramuscular |
| Subject | Relugolix | Small molecule | 120 mg | Oral |
| Subject | Triptorelin | Other / unclassified | 11.25 mg | Intramuscular |
| Background | Bicalutamide | Other / unclassified | 50 mg | Oral |